Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
The most aggressive variant of brain tumor - glioblastoma - has an average survival rate of 15 months. There is therefore an urgent need for new treatment strategies for this group of patients.
Moffitt Cancer Center and Cvergenx announced a new research partnership that aims to revolutionize radiation therapy. The goal of the Future of Radiation Therapy project is to create a framework for using a patient's genetic information to provide a personalized radiation treatment plan.
Patients undergoing conventional chemotherapy for certain cancers could potentially receive more effective and less toxic drug treatment.
The U.S. Food and Drug Administration has awarded orphan drug status to a promising immunotherapy vaccine developed at Roswell Park Cancer Institute.
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy, and radiation.
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment.
Understanding the mechanisms that give cancer cells the ability to survive and grow opens the possibility of developing improved treatments to control or cure the disease.
Glioblastoma multiforme (GBM), an extremely aggressive brain cancer, is a very complex disease. It is characterized by a fast-growing tumor in the brain composed of many subpopulations of cells, including glioblastoma stem cells, which play a crucial role in glioblastoma initiation, expansion and therapy-resistance.
Early phase Northwestern Medicine research has demonstrated a potential new therapeutic strategy for treating deadly glioblastoma brain tumors.
It's a metabolite found in essentially all our cells that, like so many things, cancer overexpresses. Now scientists have shown that when they inhibit 20-HETE, it reduces both the size of a breast cancer tumor and its ability to spread to the lungs.
In a study published today in the July 11, 2017 issue of Neurology Genetics, an official journal of the American Academy of Neurology, researchers at the New York Genome Center, The Rockefeller University and other NYGC member institutions, and IBM have illustrated the potential of IBM Watson for Genomics to analyze complex genomic data from state-of-the-art DNA sequencing of whole genomes.
New research published today, 10th July 2017, online in the journal Oncogene could offer hope to the thousands of, mainly young, people affected by the hereditary condition Neurofibromatosis 2 (NF2).
Researchers from Case Western Reserve University School of Medicine and The Cleveland Clinic designed a way to screen brain tumor cells and identify potential drug targets missed by other methods.
Patients with Alzheimer's disease have a higher risk of developing glioblastoma and a lower risk of lung cancer.
Cancerous tumors are formidable enemies, recruiting blood vessels to aid their voracious growth, damaging nearby tissues, and deploying numerous strategies to evade the body's defense systems.
While it's widely held that tumors can produce blood vessels to support their growth, scientists now have evidence that cells key to blood vessel formation can also produce tumors and enable their spread.
SCIENTISTS in the UK and India have observed a "significant" lack of 'editing' in microRNAs in brain tissue of brain cancer patients.
A new strategy for treating brain tumors may extend or save the lives of patients diagnosed with one of the deadliest forms of cancer, according to a study from UT Southwestern Medical Center.
Researchers from the Cancer Science Institute of Singapore at the National University of Singapore have discovered that the BCL6 protein could potentially be used as a marker to predict clinical outcomes of patients suffering from Glioblastoma Multiforme, the most malignant cancer of the brain.
Delivering drugs to the brain is no easy task. The blood-brain barrier -a protective sheath of tissue that shields the brain from harmful chemicals and invaders - cannot be penetrated by most therapeutics that are injected into a person's blood stream.